<DOC>
	<DOCNO>NCT02400788</DOCNO>
	<brief_summary>The purpose study assess efficacy safety combination resminostat sorafenib Asian patient advance HCC previously untreated systemic chemotherapy .</brief_summary>
	<brief_title>Resminostat ( YHI-1001 ) Combination With Sorafenib Asian Patients With Advanced Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Main Patients advance metastatic hepatocellular carcinoma Patients ECOG PS 01 Patients treated oral medication gastrointestinal function disorder consider affect absorption medication Main Patients history treatment HDAC inhibitor Pregnant woman lactate mother Patients brain metastasis suspect brain metastasis base clinical symptom</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>